Advanced Bladder Cancer: Changing the Treatment Landscape

Area of Science:

• Oncology
• Urology

Background:

• Bladder cancer is a significant global health concern, ranking as the 10th most common cancer and 13th leading cause of cancer death worldwide.
• While low-grade non-muscle-invasive bladder cancer (NMIBC) has high survival rates post-transurethral resection (TUR), muscle-invasive bladder cancer (MIBC) and metastatic disease have poor long-term prognoses.

Purpose of the Study:

• To highlight recent advancements in bladder cancer treatment modalities.
• To emphasize the critical need for personalized patient selection in optimizing therapeutic outcomes for bladder cancer.

Main Methods:

• Review of current epidemiological data on bladder cancer incidence and mortality.
• Analysis of emerging treatment strategies including immune checkpoint inhibitors (ICI), targeted therapies, and antibody-drug conjugates.
• Discussion on the genetic heterogeneity of bladder cancer and its implications for treatment selection.

Main Results:

• Recent years have seen rapid evolution in bladder cancer treatment options.
• New therapies like ICI, targeted agents, and antibody-drug conjugates offer new hope.
• Genetic heterogeneity necessitates tailored treatment approaches for improved efficacy.

Conclusions:

• Effective management of bladder cancer requires adapting to new therapeutic options.
• Personalized medicine approaches, driven by genetic profiling, are essential for improving outcomes in bladder cancer patients, particularly those with advanced disease.